Co-Diagnostics receives CE mark for Zika screening test

The company's Logix Smart Zika Test uses polymerase chain reaction technology to detect the virus. (auimeesri/iStock/Getty Images Plus)

Co-Diagnostics received a CE mark for the most recent version of its Zika virus molecular diagnostic test.

Dwight Egan, CEO of Co-Diagnostics, said the marking is a step toward meeting demand in one of the Utah-based company’s key target markets.

“Given the ability of Zika infections to be passed along through mosquito vectors as well as sexual transmission, the key component to preventing the occurrence of these tragic developmental disorders is an early, accurate, and affordable diagnosis for both men and women,” Egan said in a statement.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

According to the World Health Organization, there have been few to no confirmed cases of mosquito-based Zika virus transmission in Europe—although the same species of mosquito, Aedes aegypti, is present in certain geographic areas. The WHO recommends that certain European countries remain on alert for the disease.

The Logix Smart Zika Test uses polymerase chain reaction technology to detect the presence or absence of the virus. The company’s platform is designed to reduce the occurrence of “primer-dimers,” a potential byproduct in PCR testing that can produce a false positive result when primer molecules attach to each other, Egan said.

Co-Diagnostics is also developing a test on the platform to distinguish between Zika, dengue fever and chikungunya, three mosquito-borne diseases typically seen together in certain regions.

The Logix Smart Zika test will be manufactured at the company’s location in Utah, although Co-Diagnostics is currently not pursuing FDA approval due to the low rate of domestic Zika incidents.

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.